tiprankstipranks
Advertisement
Advertisement

PCVX Stock Latest News

Vaxcyte Shareholders Reelect Directors, Approve Governance Measures
Company AnnouncementsVaxcyte Shareholders Reelect Directors, Approve Governance Measures
16h ago
8K
PCVX
Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines
PremiumCompany Announcements
Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines
20h ago
PCVX
Vaxcyte doses first participant in VAX-A1 study
PremiumThe Fly
Vaxcyte doses first participant in VAX-A1 study
15d ago
PCVX
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
PremiumThe Fly
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
1M ago
PCVX
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
PremiumThe Fly
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
3M ago
PCVX
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
PremiumThe FlyVaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
3M ago
PCVX
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
Premium
Company Announcements
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
4M ago
PCVX
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
Premium
Company Announcements
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
4M ago
PCVX
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
PremiumRatings
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
4M ago
PCVX
Vaxcyte price target raised to $89 from $85 at BTIG
PremiumThe Fly
Vaxcyte price target raised to $89 from $85 at BTIG
4M ago
PCVX
Vaxcyte price target lowered to $133 from $134 at BofA
PremiumThe Fly
Vaxcyte price target lowered to $133 from $134 at BofA
4M ago
PCVX
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
PremiumThe Fly
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
4M ago
PCVX
Vaxcyte price target raised to $75 from $50 at TD Cowen
PremiumThe FlyVaxcyte price target raised to $75 from $50 at TD Cowen
4M ago
PCVX
Vaxcyte Launches New $500 Million ATM Equity Program
Premium
Company Announcements
Vaxcyte Launches New $500 Million ATM Equity Program
4M ago
8K
PCVX
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
Premium
The Fly
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
4M ago
PCVX
Is PCVX a Buy, Before Earnings?
PremiumPre-Earnings
Is PCVX a Buy, Before Earnings?
4M ago
PCVX
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors
PremiumCompany Announcements
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors
4M ago
PCVX
Vaxcyte doses first participants in OPUS-3 trial
PremiumThe Fly
Vaxcyte doses first participants in OPUS-3 trial
4M ago
PCVX
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
PremiumCompany Announcements
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
4M ago
8K
PCVX
Vaxcyte 11M share Spot Secondary priced at $50.00
PremiumThe FlyVaxcyte 11M share Spot Secondary priced at $50.00
5M ago
PCVX
Vaxcyte secondary being re-offered at $50 per share
Premium
The Fly
Vaxcyte secondary being re-offered at $50 per share
5M ago
PCVX
Vaxcyte offering marketed at $50 per share, Bloomberg says
Premium
The Fly
Vaxcyte offering marketed at $50 per share, Bloomberg says
5M ago
PCVX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >